ABION Inc.
KKRX:203400676.00
KRW
-14.00
(-2.03%)
ISIN
KR7203400007
Return %
Stock
S&P 500
1Y
-77.72
14.39
3Y
-82.82
81.42
5Y
- -
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Young-Gi Shin
- Full Time Employees
- 34
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Seongnam-si South Korea
- IPO Date
- Jul 21, 2014
- Website
- abionbio.com
- Similar Companies
- Business
- ABION Inc. is a South Korea-based clinical-stage biopharmaceutical company that specializes in the discovery, research, development, and commercialization of targeted therapeutics, precision oncology drugs, and innovative biological treatments. Founded in 2007 and headquartered in Seoul, South Korea, the company operates in the biotechnology and pharmaceutical industries, focusing on companion diagnostics-based precision medicine to address significant unmet medical needs in oncology and infectious diseases. ABION Inc. develops an extensive pipeline of therapeutic candidates comprising: ABN401 (vabametinib), a potent and highly selective oral small-molecule c-MET tyrosine kinase inhibitor developed for the treatment of non-small cell lung cancer characterized by MET exon 14 skipping mutations or MET amplifications; ABN501, a targeted monoclonal antibody candidate selectively directed against Claudin 3 for Claudin 3-overexpressing solid tumors, including ovarian, gastric, breast, and endometrial cancers; ABN101, an aerosolized, inhaled formulation of recombinant interferon-beta (IFN-β) engineered for broad-spectrum antiviral activity against acute respiratory viral infections; ABN202, an antibody-cytokine fusion protein candidate designed to deliver targeted immune activation within the tumor microenvironment; and proprietary companion diagnostic assays and biomarker platforms utilized to identify responsive patient populations and maximize therapeutic efficacy. The company conducts research, preclinical validation, and international clinical development operations across South Korea, the United States, and other Asia-Pacific territories. In recent developments, ABION Inc. has accelerated the global Phase 2 clinical progression of its flagship drug candidate ABN401, advancing clinical investigations for both monotherapy regimens and combination therapies with third-generation EGFR tyrosine kinase inhibitors in non-small cell lung cancer; strengthened its oncology portfolio through advanced preclinical proof-of-concept studies for its Claudin 3-targeting program ABN501; established strategic clinical and technical collaborations with international contract research organizations (CROs) and biomanufacturing partners to scale global trial operations; secured non-dilutive research and development funding and government grants from the Korea Drug Development Fund (KDDF) to accelerate clinical trial execution; and expanded international business development activities focused on out-licensing and co-development alliances with global pharmaceutical partners across North American and European markets.